EvoNext (EVE.SW) SIX CHF 0.90 intraday 26 Feb 2026: momentum, check targets
EVE.SW stock opened higher intraday on 26 Feb 2026 and trades at CHF 0.90 on the SIX exchange in Switzerland. Volume is 15,085.00 shares, above the 50-day average of 7,362.00. The move follows a 21.25% one-month gain and a recent earnings announcement on 25 Feb 2026. We track price action, technical momentum, and valuation for EvoNext Holdings S.A. as investors evaluate near-term targets and risks.
Intraday snapshot: EVE.SW stock price and flows
EVE.SW trades at CHF 0.90 with a day low of CHF 0.90 and a day high of CHF 0.98. Market cap stands at CHF 6,995,205.00 and shares outstanding are 7,211,552.00. Volume is 15,085.00, giving a relative volume near 0.98 versus the average of 7,362.00. The intraday range and volume suggest active interest after recent company updates and the 25 Feb 2026 earnings notice. source
Financials and valuation: EVE.SW stock fundamentals
EvoNext shows trailing EPS of -0.12 and a negative PE of -8.08. Book value per share is CHF 0.86 and cash per share is CHF 0.87, while the price to book is 1.12. The current ratio reads 8.34, highlighting a strong short-term liquidity buffer. These metrics show low revenue scale but solid cash coverage, and they explain mixed analyst views on valuation.
Technical picture and momentum for EVE.SW stock
Momentum indicators are bullish. RSI is 59.04 and MACD sits at 0.04 with a positive histogram. ADX at 71.10 signals a strong trend. Bollinger middle band is CHF 0.86 and upper band is CHF 1.00. Short-term momentum and a rising 50-day average (CHF 0.82) support further upside, but overbought oscillators warrant close stops.
Meyka grade and analyst context for EVE.SW stock
Meyka AI rates EVE.SW with a score out of 100. Meyka AI rates EVE.SW with a score out of 100: 68.14 / 100, Grade B, Suggestion HOLD. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. The company-level rating from other providers reads C+ (recommendation: Sell), highlighting divergent views. Use the grade as a data point, not investment advice.
Price targets, forecast and trading strategy for EVE.SW stock
Meyka AI’s forecast model projects CHF 1.84 for the next 12 months and CHF 2.48 in three years. Key intra targets today are CHF 1.20 (near) and CHF 1.84 (12-month). That implies upside of 33.33% to CHF 1.20, 104.18% to CHF 1.84, and 175.56% to CHF 2.48 from CHF 0.90. Traders should weigh low liquidity and biotech sector volatility before sizing positions. source
Sector positioning and risk factors for EVE.SW stock
EvoNext operates in Healthcare / Biotechnology, where the sector average PE is 35.67 and YTD performance is 2.53%. EVE.SW’s negative earnings and small market cap raise execution and funding risks. Positive factors include tangible book value near CHF 0.86 per share and cash coverage. Key risks: product development delays, thin trading liquidity, and dependency on licensing or partnerships.
Final Thoughts
EVE.SW stock trades at CHF 0.90 on the SIX with elevated intraday volume of 15,085.00. Technical momentum and a rising 50-day average support near-term upside, while fundamentals show negative EPS -0.12 and a negative PE -8.08. Meyka AI’s forecast model projects CHF 1.84 in 12 months, an implied upside of 104.18% versus the current price. Meyka’s grade (68.14, B, HOLD) balances liquidity and growth potential against execution risk. For active traders, watch the CHF 1.00–1.20 range for confirmation. For longer-term investors, validate clinical or licensing progress and funding runway before adding exposure. Forecasts are model-based projections and not guarantees. For more on the quote and historical data visit the Meyka stock page for EVE.SW and the company site for filings.
FAQs
What drove the intraday move in EVE.SW stock today?
Volume spikes and a recent earnings announcement on 25 Feb 2026 lifted EVE.SW stock. Technical momentum and short-term buying interest behind the 50-day average helped push price to CHF 0.90.
What are realistic price targets for EVE.SW stock?
Near-term target: CHF 1.20. 12-month model target: CHF 1.84. Three-year model target: CHF 2.48. These imply upside of 33.33% to 175.56% from CHF 0.90 and are model projections, not guarantees.
How does EvoNext’s valuation compare to the Healthcare sector?
EVE.SW shows negative EPS and a negative PE, while Healthcare peers average PE is CHF 35.67. EvoNext’s PB of 1.12 and cash per share CHF 0.87 offset some valuation concerns but reflect small-scale operations.
What are the main risks for EVE.SW investors?
Key risks include development or licensing setbacks, thin trading liquidity, and reliance on external funding. The company’s small market cap increases price volatility in stress scenarios.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.